Group 1 - The core announcement is that Kanghong Pharmaceutical's wholly-owned subsidiary, Chengdu Kanghong Biotechnology Co., Ltd., has received the Clinical Trial Approval Notice from the National Medical Products Administration for the drug KH816 injection [2] Group 2 - The approval signifies a significant step in the development of KH816 injection, indicating potential advancements in the company's product pipeline [2] - This development may enhance the company's position in the pharmaceutical industry, particularly in the area of innovative drug therapies [2] - The news reflects the regulatory progress and commitment of the company towards bringing new treatments to market [2]

Core Viewpoint - Kanghong Pharmaceutical's subsidiary, Chengdu Kanghong Biotechnology Co., has received approval from the National Medical Products Administration for the clinical trial of KH816 injection, a biosimilar of Dupilumab [1] Group 1: Product Development - KH816 injection is developed as a biosimilar to Dupilumab, which is a fully human monoclonal antibody (IgG4 type) [1] - The mechanism of action involves specific binding to the IL-4Rα subunit shared by the IL-4 and IL-13 receptor complexes, inhibiting the signaling pathways of IL-4 and IL-13 [1] Group 2: Therapeutic Indications - IL-4 and IL-13 mediated inflammation plays a crucial role in the pathogenesis of asthma, atopic dermatitis, nodular prurigo, and chronic obstructive pulmonary disease [1] - The inflammatory response involves various cell types expressing IL-4Rα, including mast cells, eosinophils, macrophages, lymphocytes, epithelial cells, and goblet cells, as well as inflammatory mediators such as histamine, leukotrienes, cytokines, and chemokines [1] Group 3: Mechanism of Action - By blocking IL-4Rα, Dupilumab can inhibit the inflammatory responses induced by IL-4 and IL-13 cytokines, including the release of pro-inflammatory cytokines, chemokines, nitric oxide, and IgE [1]

Core Viewpoint - Kanghong Pharmaceutical's subsidiary, Chengdu Kanghong Biotechnology, has received approval from the National Medical Products Administration for the clinical trial of KH816 injection, a biosimilar to Dupilumab [1] Group 1: Product Development - KH816 injection is developed as a biosimilar to Dupilumab, which is a fully human monoclonal antibody (IgG4 type) [1] - The mechanism of action involves specific binding to the IL-4Rα subunit shared by the IL-4 and IL-13 receptor complexes, inhibiting the signaling pathways of IL-4 and IL-13 [1] Group 2: Therapeutic Applications - IL-4 and IL-13 mediated inflammation is a significant component in the pathogenesis of asthma, atopic dermatitis, nodular prurigo, and chronic obstructive pulmonary disease [1] - The inflammatory response involves various cell types expressing IL-4Rα, including mast cells, eosinophils, macrophages, lymphocytes, epithelial cells, and goblet cells, as well as inflammatory mediators such as histamine, leukotrienes, cytokines, and chemokines [1] Group 3: Mechanism of Action - By blocking IL-4Rα, Dupilumab can inhibit the inflammatory responses induced by IL-4 and IL-13 cytokines, including the release of pro-inflammatory cytokines, chemokines, nitric oxide, and IgE [1]

Core Viewpoint - Kanghong Pharmaceutical announced that its wholly-owned subsidiary, Chengdu Kanghong Biotechnology Co., Ltd., received approval from the National Medical Products Administration for clinical trials of KH816 injection, a biosimilar of Dupilumab, targeting moderate to severe atopic dermatitis in adults [1]. Group 1 - The approval allows for the clinical trial of KH816 injection [1] - KH816 is developed as a biosimilar to Dupilumab [1] - The targeted clinical indication is for adult patients with moderate to severe atopic dermatitis [1]

Group 1 - The core point of the article is that Kanghong Pharmaceutical's subsidiary, Chengdu Kanghong Biotechnology Co., Ltd., has received a clinical trial approval notice from the National Medical Products Administration for the drug KH816 injection [1] Group 2 - Kanghong Pharmaceutical announced the approval on January 14, indicating progress in their drug development pipeline [1] - The article also highlights a separate case involving Haili Biotechnology, which has seen a significant valuation drop despite a previous ninefold increase due to unusual circumstances surrounding its largest client [1]

Core Viewpoint - Kanghong Pharmaceutical's subsidiary, Chengdu Kanghong Biotechnology Co., has received approval from the National Medical Products Administration for clinical trials of KH816 injection, a biosimilar to Dupilumab [1] Group 1: Product Development - KH816 is developed as a biosimilar to Dupilumab, which is a fully human monoclonal antibody (IgG4 type) [1] - The mechanism of action involves specific binding to the IL-4Rα subunit shared by IL-4 and IL-13 receptor complexes, inhibiting the signaling pathways of IL-4 and IL-13 [1] Group 2: Therapeutic Applications - IL-4 and IL-13 mediated inflammation is a significant component in the pathogenesis of asthma, atopic dermatitis, nodular prurigo, and chronic obstructive pulmonary disease [1] - The inflammatory response involves various cell types expressing IL-4Rα, including mast cells, eosinophils, macrophages, lymphocytes, epithelial cells, and goblet cells, as well as inflammatory mediators such as histamine, leukotrienes, cytokines, and chemokines [1] Group 3: Mechanism of Action - By blocking IL-4Rα, Dupilumab can inhibit the inflammatory responses induced by IL-4 and IL-13 cytokines, including the release of pro-inflammatory cytokines, chemokines, nitric oxide, and IgE [1]

证券代码：002773 证券简称：康弘药业 公告编号：2026-003 受理号：CXSL2500953 成都康弘药业集团股份有限公司 关于子公司收到药物临床试验批准通知书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 近日，成都康弘药业集团股份有限公司（以下简称"公司"）全 资子公司成都康弘生物科技有限公司（以下简称"康弘生物"）收到 国家药品监督管理局签发的《药物临床试验批准通知书》。现将相关 情况公告如下： 一． 药品基本信息 药品名称：KH816 注射液 剂型：注射剂 批准开展临床适应症：成人中重度特应性皮炎 注册分类：治疗用生物制品 3.3 类 成都康弘药业集团股份有限公司董事会 2026 年 1 月 14 日 审批结论：同意开展临床试验。 二． 产品简介 KH816 注射液是康弘生物研发的度普利尤单抗生物类似药。度普 利尤单抗是一种全人单克隆抗体（IgG4 型），可通过与白介素-4（IL-4） 和白介素-13（IL-13）受体复合物共享的 IL-4Rα 亚单位特异性结 合而抑制 IL-4 和 IL-13 的信号传导。度普利尤单抗通过 I 型受 ...

Core Viewpoint - Chengdu Kanghong Pharmaceutical Group Co., Ltd.'s subsidiary, Chengdu Hongji Biotechnology Co., Ltd., has received approval from the National Medical Products Administration for its KH631 eye injection for the treatment of Diabetic Macular Edema (DME) [1] Group 1 - The approved indication for KH631 is specifically for Diabetic Macular Edema (DME) [1]

证券日报网讯 1月12日，康弘药业在互动平台回答投资者提问时表示，截至2026年1月9日，公司股东户 数为33118户。 （文章来源：证券日报） ...

成都康弘药业集团股份有限公司 Chengdu Kanghong Pharmaceutical Group Co., Ltd 成都市金牛区蜀西路 108 号 章 程 2025 年 12 月 | ਮ | | --- | | | 成都康弘药业集团股份有限公司章程 | 3 | | --- | --- | --- | | 第一章 | 总 则 | 3 | | 第二章 | 经营宗旨和范围 | 4 | | 第三章 | 股 份 | 4 | | 第四章 | 股东和股东会 | 9 | | 第五章 | 董事会 | 26 | | 第六章 | 高级管理人员 | 39 | | 第七章 | 党的建设 | 41 | | 第八章 | 财务会计制度、利润分配和审计 | 42 | | 第九章 | 通知和公告 | 45 | | 第十章 | 合并、分立、增资、减资、解散和清算 46 | | | 第十一章 | 修改章程 | 50 | | 第十二章 | 附 则 51 | | 成都康弘药业集团股份有限公司章程 成都康弘药业集团股份有限公司章程 第一章 总 则 第一条 为维护公司、股东、职工和债权人的合法权益，规范公司的组织 和行为，根据《中华人民共和国公司法 ...